| Style | Citing Format |
|---|---|
| MLA | Naimi A, et al.. "Tumor Immunotherapies by Immune Checkpoint Inhibitors (Icis); the Pros and Cons." Cell Communication and Signaling, vol. 20, no. 1, 2022, pp. -. |
| APA | Naimi A, Mohammed RN, Raji A, Chupradit S, Yumashev AV, Suksatan W, Shalaby MN, Thangavelu L, Kamrava S, Shomali N, Sohrabi AD, Adili A, Norooziaghideh A, Razeghian E (2022). Tumor Immunotherapies by Immune Checkpoint Inhibitors (Icis); the Pros and Cons. Cell Communication and Signaling, 20(1), -. |
| Chicago | Naimi A, Mohammed RN, Raji A, Chupradit S, Yumashev AV, Suksatan W, Shalaby MN, et al.. "Tumor Immunotherapies by Immune Checkpoint Inhibitors (Icis); the Pros and Cons." Cell Communication and Signaling 20, no. 1 (2022): -. |
| Harvard | Naimi A et al. (2022) 'Tumor Immunotherapies by Immune Checkpoint Inhibitors (Icis); the Pros and Cons', Cell Communication and Signaling, 20(1), pp. -. |
| Vancouver | Naimi A, Mohammed RN, Raji A, Chupradit S, Yumashev AV, Suksatan W, et al.. Tumor Immunotherapies by Immune Checkpoint Inhibitors (Icis); the Pros and Cons. Cell Communication and Signaling. 2022;20(1):-. |
| BibTex | @article{ author = {Naimi A and Mohammed RN and Raji A and Chupradit S and Yumashev AV and Suksatan W and Shalaby MN and Thangavelu L and Kamrava S and Shomali N and Sohrabi AD and Adili A and Norooziaghideh A and Razeghian E}, title = {Tumor Immunotherapies by Immune Checkpoint Inhibitors (Icis); the Pros and Cons}, journal = {Cell Communication and Signaling}, volume = {20}, number = {1}, pages = {-}, year = {2022} } |
| RIS | TY - JOUR AU - Naimi A AU - Mohammed RN AU - Raji A AU - Chupradit S AU - Yumashev AV AU - Suksatan W AU - Shalaby MN AU - Thangavelu L AU - Kamrava S AU - Shomali N AU - Sohrabi AD AU - Adili A AU - Norooziaghideh A AU - Razeghian E TI - Tumor Immunotherapies by Immune Checkpoint Inhibitors (Icis); the Pros and Cons JO - Cell Communication and Signaling VL - 20 IS - 1 SP - EP - PY - 2022 ER - |